OCTANe Medical Technology Investors Forum gears up for healthcare value

Share

Bill Carpou

Medical technology leaders continue to discuss the best ways to approach the changing landscape of healthcare. In offering higher levels of healthcare value, Bill Carpou, CEO of OCTANe, told Medical Design & Outsourcing that improving patient outcomes will be driven by artificial intelligence, augmented reality and virtual reality.

OCTANe will be showcasing these and other important technologies during the Medical Technology Investment Forum Oct. 30-31 in Newport Beach, Calif. More than 850 executives will come together for this two-day signature event. Speakers include Medtronic CEO Omar Ishrak and AdvaMed CEO Scott Whitaker, who will focus on value-based care and FDA changes, respectively. Discussions will also include a profile of an acquisition, monetizing inventions and what’s next in medtech innovation.

In addition, the event will focus on Southern California based firms, which, according to Carpou, continue to lead the nation in medical devices, particularly in ophthalmology. Carpou said the SoCal ecosystem continues to produce more engineers than any other region in the country, providing fuel for early-stage companies and new patents. He also noted the Southern California region has seen high growth of medical device jobs, with 3,893 new medical device jobs created in the last two years.

Carpou said OCTANe will continue to support the future of local companies in the medtech space by providing greater access to capital and resources to promote growth.

“Our capital platform will align with institutional VC, corporate VC and family offices and individuals and include growth capital for those companies already up and running that can take them to a liquidity event,” he told us.

OCTANe’s growth services also give companies access to resources and expertise to enable rapid growth or revenue and EBITDA.

OCTANe’s focus for the MTIF event has expanded to include more geographic areas and industries.

“We have incorporated new technologies and innovation into the impact on improved patient outcomes while keeping down costs,” Carpou said.

How do you know your technology is disruptive enough to break conventional wisdom?

textadimage Stan Rowe knows a little something about bringing disruptive technology to market. The current Edwards Lifesciences CSO was in on the ground floor of two of medtech's most disruptive treatments, stents and transcatheter aortic valve replacement.

On December 12th, Rowe will sit down with MassDevice editor Brad Perriello for a long ranging discussion about the inside story on how these technologies came to market and what Rowe learned along the way.


Register now with the code "TAVR" and save 15% today.

Speak Your Mind

*